Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRCA-P denosumab prevention study in women with BRCA1 germline mutations
2024-513734-38-00Phase 3Authorised
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Denosumab with Placebo (2 arms). Primary endpoint: Time to occurrence of any breast cancer. Planned start Jul 2019; status: authorised.
02
Drugs
denosumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-513734-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513734-38-00.